Legend Biotech Corporation

05/26/2022 | Press release | Distributed by Public on 05/26/2022 01:18

CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Read this content
The text version of this document is not available. You can access the original document here.